| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polymerase Chain Reaction | 46 | 2022 | 6317 | 6.690 |
Why?
|
| DNA Mutational Analysis | 23 | 2022 | 4325 | 4.560 |
Why?
|
| Nucleic Acid Denaturation | 16 | 2018 | 117 | 3.490 |
Why?
|
| DNA | 35 | 2022 | 7276 | 2.820 |
Why?
|
| Nucleic Acid Amplification Techniques | 9 | 2019 | 301 | 2.100 |
Why?
|
| Gold | 13 | 2020 | 479 | 1.850 |
Why?
|
| Metal Nanoparticles | 10 | 2020 | 434 | 1.670 |
Why?
|
| DNA Probes | 4 | 2019 | 563 | 1.290 |
Why?
|
| Oligonucleotides | 5 | 2022 | 618 | 1.270 |
Why?
|
| Oligonucleotide Probes | 5 | 2019 | 435 | 1.250 |
Why?
|
| Pathology, Molecular | 3 | 2018 | 340 | 1.220 |
Why?
|
| Hydroxyl Radical | 10 | 2001 | 78 | 1.220 |
Why?
|
| Microsatellite Instability | 2 | 2021 | 674 | 1.180 |
Why?
|
| Mutation | 33 | 2022 | 29242 | 1.170 |
Why?
|
| ras Proteins | 9 | 2014 | 1122 | 1.070 |
Why?
|
| Peptide Nucleic Acids | 4 | 2013 | 23 | 1.030 |
Why?
|
| Cold Temperature | 4 | 2014 | 786 | 1.020 |
Why?
|
| Alleles | 8 | 2022 | 7123 | 1.010 |
Why?
|
| DNA, Neoplasm | 9 | 2013 | 1789 | 0.950 |
Why?
|
| Temperature | 8 | 2012 | 2146 | 0.900 |
Why?
|
| Neoplasms | 23 | 2022 | 20421 | 0.890 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 10 | 2017 | 1665 | 0.880 |
Why?
|
| Tumor Suppressor Protein p53 | 11 | 2015 | 2984 | 0.870 |
Why?
|
| Transition Temperature | 2 | 2011 | 36 | 0.830 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2022 | 3718 | 0.820 |
Why?
|
| Polymorphism, Restriction Fragment Length | 5 | 2005 | 794 | 0.810 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2014 | 4696 | 0.770 |
Why?
|
| Colonic Neoplasms | 4 | 2018 | 2564 | 0.630 |
Why?
|
| Dimethyl Sulfoxide | 4 | 2015 | 257 | 0.620 |
Why?
|
| Sequence Analysis, DNA | 5 | 2022 | 4948 | 0.620 |
Why?
|
| DNA Damage | 11 | 2016 | 2455 | 0.590 |
Why?
|
| Genetic Testing | 4 | 2014 | 3299 | 0.590 |
Why?
|
| Deoxyribonucleases | 1 | 2017 | 206 | 0.590 |
Why?
|
| Fluorescent Dyes | 8 | 2006 | 1990 | 0.580 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2016 | 382 | 0.560 |
Why?
|
| Cell Line, Tumor | 19 | 2019 | 17087 | 0.560 |
Why?
|
| DNA Primers | 7 | 2012 | 3039 | 0.550 |
Why?
|
| Endonucleases | 2 | 2016 | 390 | 0.550 |
Why?
|
| Sulfites | 5 | 2017 | 97 | 0.550 |
Why?
|
| Delivery Rooms | 2 | 2012 | 24 | 0.550 |
Why?
|
| Lipid Peroxidation | 4 | 2002 | 312 | 0.540 |
Why?
|
| DNA Methylation | 5 | 2017 | 4085 | 0.530 |
Why?
|
| Lung Neoplasms | 15 | 2020 | 12446 | 0.520 |
Why?
|
| Genes, p53 | 6 | 2012 | 775 | 0.490 |
Why?
|
| Brachytherapy | 5 | 2014 | 1284 | 0.480 |
Why?
|
| Adenocarcinoma | 8 | 2011 | 6462 | 0.470 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2018 | 759 | 0.460 |
Why?
|
| GATA5 Transcription Factor | 2 | 2010 | 20 | 0.450 |
Why?
|
| Sensitivity and Specificity | 16 | 2016 | 14895 | 0.450 |
Why?
|
| Fluoresceins | 5 | 2010 | 248 | 0.450 |
Why?
|
| Photons | 2 | 2012 | 601 | 0.430 |
Why?
|
| Aldehydes | 4 | 2000 | 200 | 0.430 |
Why?
|
| Iodine Radioisotopes | 9 | 2012 | 1042 | 0.400 |
Why?
|
| Biotin | 1 | 2011 | 275 | 0.390 |
Why?
|
| Radiometry | 9 | 2012 | 810 | 0.380 |
Why?
|
| Infant Formula | 1 | 2011 | 203 | 0.380 |
Why?
|
| Genome, Human | 5 | 2010 | 4506 | 0.370 |
Why?
|
| Breast Feeding | 3 | 2015 | 1277 | 0.370 |
Why?
|
| Base Sequence | 10 | 2014 | 13429 | 0.370 |
Why?
|
| Base Pair Mismatch | 4 | 2004 | 98 | 0.360 |
Why?
|
| Molecular Probes | 1 | 2011 | 332 | 0.360 |
Why?
|
| DNA Glycosylases | 2 | 2000 | 135 | 0.360 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2010 | 732 | 0.350 |
Why?
|
| Exons | 5 | 2015 | 2476 | 0.340 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2015 | 5227 | 0.340 |
Why?
|
| Humans | 92 | 2022 | 709431 | 0.330 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 251 | 0.320 |
Why?
|
| Ultraviolet Rays | 3 | 2022 | 1071 | 0.310 |
Why?
|
| DNA Helicases | 2 | 2002 | 834 | 0.310 |
Why?
|
| CpG Islands | 2 | 2010 | 1177 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 8864 | 0.310 |
Why?
|
| Flow Cytometry | 5 | 2002 | 6185 | 0.300 |
Why?
|
| Limit of Detection | 2 | 2021 | 249 | 0.300 |
Why?
|
| Biopsy | 1 | 2018 | 6786 | 0.290 |
Why?
|
| Biotinylation | 3 | 2019 | 188 | 0.290 |
Why?
|
| Gene Dosage | 2 | 2015 | 1273 | 0.290 |
Why?
|
| Coumarins | 6 | 1998 | 129 | 0.280 |
Why?
|
| Antigens, Nuclear | 2 | 2002 | 206 | 0.280 |
Why?
|
| Fluorescence | 7 | 2007 | 781 | 0.270 |
Why?
|
| DNA, Circular | 1 | 2004 | 104 | 0.270 |
Why?
|
| Endothelium, Vascular | 3 | 2015 | 4668 | 0.260 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2015 | 4090 | 0.260 |
Why?
|
| Fluorescein | 2 | 2002 | 170 | 0.250 |
Why?
|
| Neutrons | 5 | 1990 | 78 | 0.250 |
Why?
|
| Gene Amplification | 1 | 2008 | 1089 | 0.250 |
Why?
|
| Genetic Techniques | 1 | 2007 | 441 | 0.250 |
Why?
|
| Radiotherapy Dosage | 11 | 2014 | 2903 | 0.240 |
Why?
|
| Monte Carlo Method | 4 | 2015 | 1304 | 0.240 |
Why?
|
| Nucleic Acid Hybridization | 4 | 2010 | 1456 | 0.240 |
Why?
|
| Genomic Instability | 2 | 2005 | 698 | 0.240 |
Why?
|
| Radiation Dosage | 8 | 2010 | 2044 | 0.240 |
Why?
|
| Copper | 2 | 1996 | 390 | 0.240 |
Why?
|
| Prostheses and Implants | 2 | 2009 | 1330 | 0.240 |
Why?
|
| Tenascin | 1 | 2002 | 58 | 0.230 |
Why?
|
| N-Glycosyl Hydrolases | 2 | 2000 | 71 | 0.230 |
Why?
|
| Workflow | 2 | 2018 | 803 | 0.230 |
Why?
|
| Idoxuridine | 6 | 2002 | 123 | 0.230 |
Why?
|
| Electrons | 4 | 2010 | 269 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2007 | 2909 | 0.220 |
Why?
|
| Fluorometry | 4 | 2010 | 119 | 0.220 |
Why?
|
| DNA, Complementary | 2 | 2002 | 2118 | 0.220 |
Why?
|
| Ethanolamines | 1 | 2002 | 153 | 0.220 |
Why?
|
| Histones | 4 | 1996 | 2585 | 0.210 |
Why?
|
| Indicators and Reagents | 2 | 2014 | 491 | 0.210 |
Why?
|
| Neovascularization, Pathologic | 5 | 2015 | 2723 | 0.210 |
Why?
|
| Endothelial Cells | 2 | 2012 | 3398 | 0.210 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 2 | 1990 | 67 | 0.210 |
Why?
|
| Bleomycin | 2 | 1999 | 507 | 0.210 |
Why?
|
| Artifacts | 4 | 2018 | 1900 | 0.210 |
Why?
|
| Alu Elements | 1 | 2021 | 104 | 0.210 |
Why?
|
| Ligases | 1 | 2002 | 357 | 0.200 |
Why?
|
| Cell Line | 8 | 2021 | 16795 | 0.200 |
Why?
|
| Formaldehyde | 3 | 2007 | 363 | 0.200 |
Why?
|
| Transistors, Electronic | 2 | 2011 | 24 | 0.190 |
Why?
|
| Metals | 2 | 2008 | 681 | 0.190 |
Why?
|
| Particle Accelerators | 2 | 2010 | 189 | 0.190 |
Why?
|
| Polylysine | 6 | 1997 | 139 | 0.180 |
Why?
|
| 2,2'-Dipyridyl | 1 | 1998 | 10 | 0.180 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 1998 | 18 | 0.180 |
Why?
|
| Nucleic Acid Conformation | 1 | 2003 | 1031 | 0.180 |
Why?
|
| Gamma Rays | 8 | 2012 | 334 | 0.180 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2019 | 600 | 0.180 |
Why?
|
| Cyclic N-Oxides | 1 | 1998 | 79 | 0.180 |
Why?
|
| Phosphatidylethanolamines | 1 | 1998 | 139 | 0.180 |
Why?
|
| Patient Discharge | 1 | 2011 | 2963 | 0.180 |
Why?
|
| Electrophoresis, Capillary | 1 | 2018 | 72 | 0.170 |
Why?
|
| Genotype | 7 | 2009 | 12955 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2016 | 15548 | 0.170 |
Why?
|
| Internet | 1 | 2011 | 3076 | 0.170 |
Why?
|
| Radiation Monitoring | 2 | 1990 | 99 | 0.170 |
Why?
|
| Microsatellite Repeats | 3 | 2005 | 812 | 0.170 |
Why?
|
| Molecular Sequence Data | 5 | 2014 | 18883 | 0.170 |
Why?
|
| Radioisotopes | 2 | 2010 | 513 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 1999 | 681 | 0.160 |
Why?
|
| INDEL Mutation | 1 | 2018 | 260 | 0.160 |
Why?
|
| Peroxides | 1 | 1997 | 69 | 0.160 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2005 | 1087 | 0.160 |
Why?
|
| Chromatin | 2 | 1999 | 2683 | 0.160 |
Why?
|
| Macular Degeneration | 2 | 2015 | 938 | 0.160 |
Why?
|
| Energy Transfer | 4 | 1989 | 106 | 0.150 |
Why?
|
| Boron Compounds | 1 | 1997 | 177 | 0.150 |
Why?
|
| Genome | 1 | 2004 | 1729 | 0.150 |
Why?
|
| Nanoparticles | 3 | 2016 | 2054 | 0.150 |
Why?
|
| Plasmids | 4 | 2010 | 2516 | 0.150 |
Why?
|
| Spectrometry, Fluorescence | 6 | 1999 | 730 | 0.150 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 572 | 0.140 |
Why?
|
| Information Management | 1 | 2015 | 93 | 0.140 |
Why?
|
| Genes, p16 | 1 | 2015 | 162 | 0.140 |
Why?
|
| Erythrocyte Membrane | 1 | 1997 | 444 | 0.140 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 912 | 0.140 |
Why?
|
| Radiosurgery | 2 | 2015 | 1347 | 0.140 |
Why?
|
| Silicon Dioxide | 1 | 2016 | 257 | 0.140 |
Why?
|
| Tissue Fixation | 2 | 2007 | 261 | 0.130 |
Why?
|
| Erythrocytes | 3 | 2002 | 2477 | 0.130 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 1001 | 0.130 |
Why?
|
| Molecular Structure | 4 | 2022 | 2020 | 0.130 |
Why?
|
| Nucleosomes | 1 | 1998 | 480 | 0.130 |
Why?
|
| Cattle | 5 | 1999 | 4024 | 0.130 |
Why?
|
| Drug Implants | 1 | 2014 | 241 | 0.130 |
Why?
|
| DNA-Binding Proteins | 5 | 2006 | 9802 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 2463 | 0.130 |
Why?
|
| Paraffin Embedding | 2 | 2006 | 319 | 0.130 |
Why?
|
| Reactive Oxygen Species | 1 | 2002 | 2137 | 0.130 |
Why?
|
| Hydroxides | 1 | 1993 | 49 | 0.120 |
Why?
|
| Radiotherapy, High-Energy | 3 | 1994 | 244 | 0.120 |
Why?
|
| Nucleic Acid Heteroduplexes | 2 | 2003 | 47 | 0.120 |
Why?
|
| Breast Neoplasms | 5 | 2022 | 19798 | 0.120 |
Why?
|
| DNA Repair | 2 | 2018 | 2032 | 0.120 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 19470 | 0.120 |
Why?
|
| Apoptosis | 2 | 2015 | 10133 | 0.120 |
Why?
|
| DNA Ligases | 2 | 2002 | 85 | 0.120 |
Why?
|
| Biocompatible Materials | 1 | 2021 | 1722 | 0.120 |
Why?
|
| Male | 20 | 2021 | 351848 | 0.120 |
Why?
|
| Dose-Response Relationship, Radiation | 6 | 2012 | 924 | 0.120 |
Why?
|
| Piperazines | 1 | 2003 | 2606 | 0.120 |
Why?
|
| Chitosan | 2 | 2010 | 141 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 4853 | 0.110 |
Why?
|
| Phantoms, Imaging | 2 | 2012 | 2397 | 0.110 |
Why?
|
| DNA, Viral | 1 | 1999 | 2302 | 0.110 |
Why?
|
| Doxorubicin | 2 | 2010 | 2238 | 0.110 |
Why?
|
| Light | 1 | 1998 | 1420 | 0.110 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2012 | 397 | 0.110 |
Why?
|
| Gadolinium | 1 | 2016 | 907 | 0.110 |
Why?
|
| Time Factors | 9 | 2014 | 41295 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2003 | 2959 | 0.110 |
Why?
|
| Genes, erbB-1 | 1 | 2011 | 169 | 0.100 |
Why?
|
| Models, Biological | 5 | 2014 | 9941 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 1936 | 0.100 |
Why?
|
| Nanomedicine | 1 | 2014 | 324 | 0.100 |
Why?
|
| Solutions | 3 | 1997 | 417 | 0.100 |
Why?
|
| Free Radicals | 3 | 1997 | 256 | 0.100 |
Why?
|
| Benzene Derivatives | 2 | 2002 | 58 | 0.100 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2010 | 90 | 0.100 |
Why?
|
| Freezing | 1 | 2011 | 303 | 0.100 |
Why?
|
| Rats, Inbred F344 | 3 | 2002 | 883 | 0.100 |
Why?
|
| Radiation Effects | 1 | 1990 | 82 | 0.100 |
Why?
|
| Infant Care | 1 | 2012 | 186 | 0.100 |
Why?
|
| HeLa Cells | 3 | 2012 | 3274 | 0.100 |
Why?
|
| Hydroxylamine | 2 | 2000 | 16 | 0.100 |
Why?
|
| Coffee | 1 | 2015 | 550 | 0.100 |
Why?
|
| beta-Globins | 1 | 2010 | 124 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2015 | 504 | 0.100 |
Why?
|
| Personnel, Hospital | 1 | 2012 | 291 | 0.100 |
Why?
|
| Oxides | 1 | 2011 | 423 | 0.100 |
Why?
|
| Photochemistry | 2 | 2001 | 247 | 0.100 |
Why?
|
| Cell Survival | 6 | 2015 | 6184 | 0.100 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 2 | 1999 | 39 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2005 | 1665 | 0.090 |
Why?
|
| Postnatal Care | 1 | 2011 | 226 | 0.090 |
Why?
|
| Organizational Policy | 1 | 2012 | 438 | 0.090 |
Why?
|
| Fiducial Markers | 1 | 2010 | 137 | 0.090 |
Why?
|
| Radiation Tolerance | 2 | 2015 | 514 | 0.090 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 506 | 0.090 |
Why?
|
| Polyglycolic Acid | 1 | 2010 | 429 | 0.090 |
Why?
|
| Dental Restoration, Permanent | 1 | 2009 | 123 | 0.090 |
Why?
|
| beta-Thalassemia | 1 | 2010 | 232 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 3 | 2010 | 6077 | 0.090 |
Why?
|
| Ascorbic Acid | 3 | 2001 | 639 | 0.090 |
Why?
|
| Equipment Design | 2 | 2015 | 3636 | 0.090 |
Why?
|
| Genomics | 1 | 2004 | 5250 | 0.090 |
Why?
|
| Iron | 1 | 1996 | 1720 | 0.080 |
Why?
|
| Codon | 2 | 2007 | 623 | 0.080 |
Why?
|
| Nanotechnology | 1 | 2014 | 775 | 0.080 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 76 | 0.080 |
Why?
|
| Terminology as Topic | 1 | 2015 | 1632 | 0.080 |
Why?
|
| Plastics | 1 | 2008 | 119 | 0.080 |
Why?
|
| Reference Standards | 1 | 2010 | 890 | 0.080 |
Why?
|
| Animals | 23 | 2021 | 170647 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 13763 | 0.080 |
Why?
|
| Hydrogen Peroxide | 3 | 2001 | 729 | 0.080 |
Why?
|
| Indoles | 1 | 2015 | 1899 | 0.080 |
Why?
|
| Equipment Contamination | 1 | 2008 | 178 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 1428 | 0.080 |
Why?
|
| Skin Physiological Phenomena | 1 | 2007 | 182 | 0.080 |
Why?
|
| Fixatives | 1 | 2006 | 102 | 0.080 |
Why?
|
| Activation Analysis | 1 | 1985 | 2 | 0.080 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2011 | 815 | 0.070 |
Why?
|
| Neutron Activation Analysis | 1 | 1985 | 36 | 0.070 |
Why?
|
| Radiotherapy | 2 | 2010 | 1627 | 0.070 |
Why?
|
| Quinazolines | 1 | 2013 | 1426 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2015 | 1946 | 0.070 |
Why?
|
| Microcirculation | 1 | 2010 | 1292 | 0.070 |
Why?
|
| Pregnancy | 4 | 2022 | 26811 | 0.070 |
Why?
|
| Delayed-Action Preparations | 1 | 2009 | 1006 | 0.070 |
Why?
|
| Genetic Heterogeneity | 1 | 2009 | 752 | 0.070 |
Why?
|
| Drug Carriers | 1 | 2010 | 716 | 0.070 |
Why?
|
| Gene Expression Profiling | 5 | 2009 | 9584 | 0.070 |
Why?
|
| Quality Control | 2 | 2012 | 876 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2002 | 6659 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 1137 | 0.070 |
Why?
|
| Lactic Acid | 1 | 2010 | 1120 | 0.070 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2004 | 72 | 0.070 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2007 | 434 | 0.070 |
Why?
|
| Substrate Specificity | 1 | 2009 | 1967 | 0.070 |
Why?
|
| Genes, ras | 1 | 2007 | 730 | 0.070 |
Why?
|
| Molecular Probe Techniques | 1 | 2004 | 118 | 0.070 |
Why?
|
| Apolipoproteins B | 1 | 2006 | 412 | 0.060 |
Why?
|
| Carcinoma | 1 | 2015 | 2330 | 0.060 |
Why?
|
| Microspheres | 2 | 2001 | 799 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4976 | 0.060 |
Why?
|
| Cell Cycle Proteins | 3 | 2006 | 3513 | 0.060 |
Why?
|
| Ferrous Compounds | 2 | 2001 | 45 | 0.060 |
Why?
|
| Prenatal Diagnosis | 1 | 2010 | 1142 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2007 | 559 | 0.060 |
Why?
|
| Developing Countries | 1 | 2015 | 2675 | 0.060 |
Why?
|
| HCT116 Cells | 1 | 2004 | 413 | 0.060 |
Why?
|
| RNA Ligase (ATP) | 1 | 2002 | 16 | 0.060 |
Why?
|
| Indium Radioisotopes | 2 | 1995 | 122 | 0.060 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2003 | 193 | 0.060 |
Why?
|
| Bacteriophage T4 | 1 | 2002 | 36 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2012 | 3030 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2015 | 2214 | 0.060 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 2283 | 0.060 |
Why?
|
| Vitamin E Deficiency | 1 | 2002 | 37 | 0.060 |
Why?
|
| Expressed Sequence Tags | 1 | 2002 | 262 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2015 | 3195 | 0.060 |
Why?
|
| Ficusin | 1 | 2001 | 16 | 0.060 |
Why?
|
| Radioimmunotherapy | 1 | 2021 | 78 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2010 | 1549 | 0.050 |
Why?
|
| Cesium Radioisotopes | 2 | 1993 | 38 | 0.050 |
Why?
|
| Edetic Acid | 1 | 2001 | 286 | 0.050 |
Why?
|
| Guanine | 1 | 2002 | 282 | 0.050 |
Why?
|
| Heteroduplex Analysis | 1 | 2000 | 9 | 0.050 |
Why?
|
| Female | 13 | 2022 | 377269 | 0.050 |
Why?
|
| Cobalt Radioisotopes | 2 | 1992 | 79 | 0.050 |
Why?
|
| Umbelliferones | 1 | 1999 | 10 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 2987 | 0.050 |
Why?
|
| Deoxyribonucleotides | 1 | 1999 | 46 | 0.050 |
Why?
|
| Succinimides | 2 | 1996 | 87 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2004 | 695 | 0.050 |
Why?
|
| Tissue Distribution | 3 | 2014 | 2443 | 0.050 |
Why?
|
| DNA, Superhelical | 1 | 1999 | 54 | 0.050 |
Why?
|
| Bacteriophage M13 | 1 | 1999 | 39 | 0.050 |
Why?
|
| Algorithms | 2 | 2010 | 13668 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2004 | 1383 | 0.050 |
Why?
|
| Benzoyl Peroxide | 1 | 1998 | 11 | 0.050 |
Why?
|
| Mice | 10 | 2021 | 80950 | 0.050 |
Why?
|
| Ethidium | 1 | 1998 | 31 | 0.050 |
Why?
|
| RNA | 1 | 2009 | 2671 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2004 | 740 | 0.050 |
Why?
|
| Hydroxylamines | 1 | 1998 | 42 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2003 | 683 | 0.040 |
Why?
|
| Free Radical Scavengers | 2 | 1996 | 232 | 0.040 |
Why?
|
| Health Promotion | 1 | 2011 | 2180 | 0.040 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1998 | 119 | 0.040 |
Why?
|
| Endodeoxyribonucleases | 1 | 2019 | 172 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 2282 | 0.040 |
Why?
|
| Gliosarcoma | 1 | 1998 | 120 | 0.040 |
Why?
|
| Lung | 2 | 2002 | 9617 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2015 | 24403 | 0.040 |
Why?
|
| Oximes | 1 | 1999 | 319 | 0.040 |
Why?
|
| Hydrazines | 1 | 1999 | 228 | 0.040 |
Why?
|
| Phycoerythrin | 1 | 1997 | 9 | 0.040 |
Why?
|
| Benzamides | 1 | 2003 | 1417 | 0.040 |
Why?
|
| Recurrence | 1 | 2009 | 8279 | 0.040 |
Why?
|
| DNA, Single-Stranded | 1 | 1999 | 373 | 0.040 |
Why?
|
| Amidines | 1 | 1997 | 39 | 0.040 |
Why?
|
| Computer Simulation | 4 | 2014 | 6059 | 0.040 |
Why?
|
| Adenine | 1 | 2002 | 913 | 0.040 |
Why?
|
| Glioblastoma | 1 | 2012 | 3337 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 1989 | 3580 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 1999 | 384 | 0.040 |
Why?
|
| Chemistry, Physical | 1 | 1996 | 164 | 0.040 |
Why?
|
| Singlet Oxygen | 1 | 1996 | 49 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 3946 | 0.040 |
Why?
|
| Osteosarcoma | 1 | 2002 | 891 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2020 | 3895 | 0.040 |
Why?
|
| Colorectal Neoplasms | 3 | 2012 | 6564 | 0.040 |
Why?
|
| Cricetinae | 2 | 1992 | 2586 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2002 | 1353 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 1807 | 0.040 |
Why?
|
| Point Mutation | 1 | 2002 | 1669 | 0.040 |
Why?
|
| Chemical Phenomena | 1 | 1996 | 568 | 0.040 |
Why?
|
| Molecular Weight | 1 | 1999 | 2518 | 0.040 |
Why?
|
| Radionuclide Imaging | 2 | 1990 | 2039 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2006 | 2285 | 0.040 |
Why?
|
| Carbon Radioisotopes | 1 | 1997 | 630 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2002 | 11384 | 0.040 |
Why?
|
| Cost Savings | 1 | 2001 | 923 | 0.040 |
Why?
|
| Brain Neoplasms | 2 | 2012 | 8756 | 0.040 |
Why?
|
| Solvents | 1 | 1996 | 300 | 0.040 |
Why?
|
| Homozygote | 1 | 2000 | 1840 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 1932 | 0.030 |
Why?
|
| Organizations, Nonprofit | 1 | 2015 | 114 | 0.030 |
Why?
|
| X-Rays | 1 | 2015 | 295 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 2694 | 0.030 |
Why?
|
| Rats | 3 | 2002 | 25068 | 0.030 |
Why?
|
| Purines | 1 | 1998 | 604 | 0.030 |
Why?
|
| Fluorescence Polarization | 1 | 1994 | 135 | 0.030 |
Why?
|
| DNA, Recombinant | 1 | 1995 | 506 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 671 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2002 | 1987 | 0.030 |
Why?
|
| Prostate | 1 | 2002 | 1546 | 0.030 |
Why?
|
| Radiation, Ionizing | 2 | 2006 | 277 | 0.030 |
Why?
|
| Liver | 1 | 1990 | 7629 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 3660 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2016 | 956 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 2853 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2014 | 4903 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 658 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1996 | 1530 | 0.030 |
Why?
|
| Avidin | 1 | 1993 | 46 | 0.030 |
Why?
|
| Ovarian Neoplasms | 2 | 2006 | 4727 | 0.030 |
Why?
|
| Heterozygote | 1 | 2000 | 2786 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 1994 | 588 | 0.030 |
Why?
|
| Capacity Building | 1 | 2015 | 252 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2019 | 867 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2001 | 2858 | 0.030 |
Why?
|
| Methods | 1 | 1993 | 1192 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 417 | 0.030 |
Why?
|
| Endothelium | 1 | 2015 | 812 | 0.030 |
Why?
|
| Transfection | 2 | 2015 | 6193 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 3955 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 4385 | 0.030 |
Why?
|
| Lasers | 1 | 2016 | 938 | 0.030 |
Why?
|
| United Nations | 1 | 2012 | 154 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 3756 | 0.030 |
Why?
|
| Eye | 1 | 2015 | 718 | 0.030 |
Why?
|
| Glioma | 1 | 2006 | 3272 | 0.030 |
Why?
|
| Radiation | 1 | 1990 | 53 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 1935 | 0.030 |
Why?
|
| Nuclear Proteins | 2 | 2006 | 5992 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 1996 | 2345 | 0.030 |
Why?
|
| Water | 2 | 1994 | 1322 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 804 | 0.020 |
Why?
|
| Polymethyl Methacrylate | 1 | 2010 | 132 | 0.020 |
Why?
|
| Drug Stability | 1 | 2010 | 309 | 0.020 |
Why?
|
| Serum Albumin | 1 | 1993 | 687 | 0.020 |
Why?
|
| Thallium Radioisotopes | 1 | 1989 | 150 | 0.020 |
Why?
|
| Fast Neutrons | 1 | 1989 | 18 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2015 | 2866 | 0.020 |
Why?
|
| Radiopharmaceuticals | 3 | 2010 | 2710 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 2568 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2963 | 0.020 |
Why?
|
| Ascites | 1 | 1991 | 344 | 0.020 |
Why?
|
| Weights and Measures | 1 | 1989 | 41 | 0.020 |
Why?
|
| Technology, Radiologic | 1 | 1990 | 171 | 0.020 |
Why?
|
| Technetium | 1 | 1989 | 354 | 0.020 |
Why?
|
| Autoradiography | 1 | 1990 | 797 | 0.020 |
Why?
|
| Half-Life | 1 | 1990 | 685 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2010 | 244 | 0.020 |
Why?
|
| Dental Amalgam | 1 | 2009 | 66 | 0.020 |
Why?
|
| Radioactivity | 1 | 1989 | 61 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 437 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2006 | 8733 | 0.020 |
Why?
|
| Dental Materials | 1 | 2009 | 94 | 0.020 |
Why?
|
| Radioactive Fallout | 1 | 1988 | 7 | 0.020 |
Why?
|
| Certification | 1 | 2012 | 411 | 0.020 |
Why?
|
| Nuclear Reactors | 1 | 1988 | 9 | 0.020 |
Why?
|
| Ethylenes | 1 | 1988 | 41 | 0.020 |
Why?
|
| Contrast Media | 1 | 2002 | 5260 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 4012 | 0.020 |
Why?
|
| Adsorption | 1 | 2008 | 216 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 4282 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1990 | 1482 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2000 | 4402 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2009 | 23519 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 1989 | 345 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17347 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8941 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5508 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 1214 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2015 | 1091 | 0.020 |
Why?
|
| Accidents | 1 | 1988 | 167 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 10551 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2002 | 13351 | 0.020 |
Why?
|
| United States | 2 | 2012 | 67177 | 0.020 |
Why?
|
| Urban Population | 1 | 2015 | 2031 | 0.020 |
Why?
|
| World Health Organization | 1 | 2012 | 1276 | 0.020 |
Why?
|
| Neoplasm Transplantation | 2 | 2002 | 2190 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2006 | 136 | 0.020 |
Why?
|
| Radiation Protection | 1 | 1990 | 459 | 0.020 |
Why?
|
| Polyethylenes | 1 | 1988 | 272 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 13363 | 0.020 |
Why?
|
| Oxygen | 1 | 1996 | 4148 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2007 | 875 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 5168 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 50734 | 0.020 |
Why?
|
| Methylation | 1 | 2006 | 1123 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2010 | 1631 | 0.010 |
Why?
|
| Muscles | 1 | 1988 | 1620 | 0.010 |
Why?
|
| Radiobiology | 1 | 2002 | 91 | 0.010 |
Why?
|
| Kinetics | 1 | 2010 | 6893 | 0.010 |
Why?
|
| Boston | 1 | 2015 | 9409 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 11904 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7740 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2002 | 536 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2015 | 3280 | 0.010 |
Why?
|
| Prognosis | 1 | 2020 | 29148 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 39394 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 1998 | 285 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2004 | 1638 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 18384 | 0.010 |
Why?
|
| Software | 1 | 1990 | 4351 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 1998 | 553 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 3032 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1994 | 378 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 4787 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 7497 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2002 | 2426 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 1994 | 335 | 0.010 |
Why?
|
| Biophysics | 1 | 1994 | 395 | 0.010 |
Why?
|
| Adult | 2 | 2020 | 212298 | 0.010 |
Why?
|
| Chelating Agents | 1 | 1995 | 409 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 34274 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 34096 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 8069 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2006 | 5177 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 39650 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2007 | 5067 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 71151 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1995 | 2643 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 7988 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1991 | 748 | 0.010 |
Why?
|
| Ukraine | 1 | 1988 | 96 | 0.010 |
Why?
|
| Greece | 1 | 1988 | 346 | 0.010 |
Why?
|
| Binding Sites | 1 | 1995 | 6335 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 12468 | 0.000 |
Why?
|
| Risk Factors | 1 | 1990 | 70264 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1991 | 3032 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1991 | 10603 | 0.000 |
Why?
|
| Brain | 1 | 1998 | 24936 | 0.000 |
Why?
|